Training Collections
Library Memberships
On-demand course library with video lectures, expert case reviews, and more
Fellowship Certificate™ Programs
Practice-focused training programs designed to help you gain experience in a specific subspecialty area.
Ultimate Learning Pass
Unlock access to our full Course Library and all self-paced Fellowships.
Continuing Medical Education (State CME)
Complete all of your state CME requirements in one convenient place.
Noon Conference (Free)
Get access to free live lectures, every week, from top radiologists.
Case of the Week (Free)
Get a free weekly case delivered right to your inbox.
Case Crunch: Rapid Case Review (Free)
Register for free live board reviews.
Dr. Resnick's MSK Conference
Learn directly from the MSK Master himself.
Lower Extremities MRI Conference
Musculoskeletal Imaging
PET Imaging
Pediatric Imaging
For Training Programs
Supplement your training program with case-based learning for residents, registrars, fellows, and more.
For Private Practices
Upskill in high growth, advanced imaging areas.
Compliance
NewTrack, fulfill, and report on all your radiologists' credentialing and licensing requirements.
Emergency Call Prep
Prepare trainees to be on call for the emergency department with this specialized training series.
Training Collections
Library Memberships
On-demand course library with video lectures, expert case reviews, and more
Fellowship Certificate™ Programs
Practice-focused training programs designed to help you gain experience in a specific subspecialty area.
Ultimate Learning Pass
Unlock access to our full Course Library and all self-paced Fellowships.
Continuing Medical Education (State CME)
Complete all of your state CME requirements in one convenient place.
Noon Conference (Free)
Get access to free live lectures, every week, from top radiologists.
Case of the Week (Free)
Get a free weekly case delivered right to your inbox.
Case Crunch: Rapid Case Review (Free)
Register for free live board reviews.
Dr. Resnick's MSK Conference
Learn directly from the MSK Master himself.
Lower Extremities MRI Conference
Musculoskeletal Imaging
PET Imaging
Pediatric Imaging
For Training Programs
Supplement your training program with case-based learning for residents, registrars, fellows, and more.
For Private Practices
Upskill in high growth, advanced imaging areas.
Compliance
NewTrack, fulfill, and report on all your radiologists' credentialing and licensing requirements.
Emergency Call Prep
Prepare trainees to be on call for the emergency department with this specialized training series.
Lesson
Introduction to PET/CT Imaging
12 topics, 49 min.
Introduction to PET/CT Imaging
1 m.How to Use the Case Viewer to Evaluate PET/CT Images in this Course
2 m.What is PET/CT Imaging?
7 m.Commonly Used Positron-emitting Radionuclides
2 m.PET/CT Imaging Acquisition
4 m.PET/CT Quality Control
5 m.Quantification of Tracer Uptake
6 m.Factors Impacting Quantification of Tracer Uptake
3 m.Where to Start: Reading a PET/CT Study
9 m.Case: Systematic Approach to Reading a PET/CT Study
9 m.Case: Setting Up Your Imaging Display for a PET/CT Study
5 m.PET/CT Report Example
2 m.Lesson
FDG Use in PET/CT
8 topics, 28 min.
Introduction to FDG
4 m.FDG: Patient Preparation
2 m.FDG: Patterns of Muscle Uptake
6 m.FDG: Patterns of Bone Marrow Uptake and the Effects of G-CSF
5 m.FDG: Patterns of Bone Marrow Uptake and the Effects of Bone Marrow Disease
3 m.Case: Normal Distribution of FDG Tracer
4 m.Case: Abnormal Distribution of FDG (Hyperinsulinemia)
6 m.Cases: Abnormal Distribution of FDG (Hyperinsulinemia, Rhabdomyolysis, Myositis)
2 m.Lesson
FDG: Common Pitfalls and Benign Lesions
9 topics, 21 min.
Lesson
FDG Use in Hematologic Malignancies
8 topics, 40 min.
Role of FDG PET/CT Imaging in Lymphoma: Classification and Staging
7 m.Role of FDG PET/CT Imaging in Lymphoma: Response to Therapy
3 m.Role of FDG PET/CT Imaging in Lymphoma: Follow-up Reports
3 m.FDG Case: Hodgkin's Lymphoma, Initial Presentation
9 m.FDG Case: Hodgkin's Lymphoma, Follow-up
6 m.FDG Case: DLBCL, Initial Presentation
5 m.FDG Case: DLBCL, Follow-up
5 m.FDG Case: Multiple Myeloma
7 m.Lesson
FDG Use in Lung Cancer
5 topics, 17 min.
Lesson
FDG Use in Head & Neck Cancer
3 topics, 14 min.
Lesson
FDG Use in Breast Cancer
2 topics, 8 min.
Lesson
FDG Use in Immunotherapy
3 topics, 18 min.
Lesson
DOTATATE Use in PET/CT
7 topics, 15 min.
Lesson
DOTATATE and FDG Use in Neuroendocrine Tumors
6 topics, 22 min.
Lesson
PSMA Use in PET/CT
4 topics, 9 min.
Lesson
PSMA Use in Prostate Cancer
5 topics, 23 min.
0:00
In this video, we are going
0:02
to discuss a different tracer called PSMA.
0:06
That stands for prostate specific Membrane Antigen,
0:10
and we're gonna cover some basics of this.
0:13
Agent. PSMA is
0:16
a type two transmembrane glycoprotein that is
0:20
over expressed by up to a thousand fold
0:25
in prostate cancer epithelial cells.
0:28
This is the basic, uh, reason why we are
0:33
using this tracer for prostate cancer patients.
0:37
This glycoprotein can be labeled both to
0:42
F 18 and gallium 68,
0:45
and both agents will give us, uh, good clinical
0:50
and diagnostic information.
0:53
There is limited data
0:54
and direct comparison of these CI tracers.
0:56
So the use
0:59
of one versus the other would be mostly
1:03
depending upon the, uh, availability of the agent
1:07
and the clinical preference.
1:11
PMA has demonstrated superior accuracy over conventional
1:15
imaging for staging high-risk patients.
1:18
Currently, conventional imaging includes CT or MRI
1:23
and bone scans.
1:25
It is also very sensitive in detecting disease in patients
1:29
with biochemical recurrence, even at low PSA levels.
1:33
So the clinical
1:35
scenarios in which this tracer has been FDA approved are the
1:39
following primary staging or high risk prostate cancer.
1:43
Those are patients with a Gleason score higher than seven
1:47
or a high PSA level, as well as patients
1:52
with biochemical recurrence in patients
1:55
with castration-resistant prostate cancer.
1:58
These agent is also used for
2:02
determining eligibility for lutetium PSMA,
2:06
which is a radioligand therapy.
2:09
And, uh, there is, uh, literature regarding the use
2:13
of this tracer to localize prosthetic disease,
2:17
to guide biopsy, although this is not the common indication
2:22
that you will see probably in practice.
Introduction to PSMA
HIDEInteractive Transcript
0:00
In this video, we are going
0:02
to discuss a different tracer called PSMA.
0:06
That stands for prostate specific Membrane Antigen,
0:10
and we're gonna cover some basics of this.
0:13
Agent. PSMA is
0:16
a type two transmembrane glycoprotein that is
0:20
over expressed by up to a thousand fold
0:25
in prostate cancer epithelial cells.
0:28
This is the basic, uh, reason why we are
0:33
using this tracer for prostate cancer patients.
0:37
This glycoprotein can be labeled both to
0:42
F 18 and gallium 68,
0:45
and both agents will give us, uh, good clinical
0:50
and diagnostic information.
0:53
There is limited data
0:54
and direct comparison of these CI tracers.
0:56
So the use
0:59
of one versus the other would be mostly
1:03
depending upon the, uh, availability of the agent
1:07
and the clinical preference.
1:11
PMA has demonstrated superior accuracy over conventional
1:15
imaging for staging high-risk patients.
1:18
Currently, conventional imaging includes CT or MRI
1:23
and bone scans.
1:25
It is also very sensitive in detecting disease in patients
1:29
with biochemical recurrence, even at low PSA levels.
1:33
So the clinical
1:35
scenarios in which this tracer has been FDA approved are the
1:39
following primary staging or high risk prostate cancer.
1:43
Those are patients with a Gleason score higher than seven
1:47
or a high PSA level, as well as patients
1:52
with biochemical recurrence in patients
1:55
with castration-resistant prostate cancer.
1:58
These agent is also used for
2:02
determining eligibility for lutetium PSMA,
2:06
which is a radioligand therapy.
2:09
And, uh, there is, uh, literature regarding the use
2:13
of this tracer to localize prosthetic disease,
2:17
to guide biopsy, although this is not the common indication
2:22
that you will see probably in practice.
Report
Faculty
Elisa Franquet Elia, MD
Assistant Professor of Radiology
UMass Chan Medical School
Tags
Prostate/seminal vesicles
PET/CT PSMA
PET
Oncologic Imaging
Nuclear Medicine
Neoplastic
Genitourinary (GU)
© 2026 Medality. All Rights Reserved.
